Do GLP-1 drugs affect fertility? (men + women)

GLP-1 drugs like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) were built to lower blood sugar and trigger weight loss, not to change fertility. But losing a lot of weight reshapes the hormones that drive ovulation in women and sperm production in men, so the question of how these drugs touch fertility is real and it splits sharply by sex, body weight, and whether someone is trying to conceive or trying to avoid it. This guide walks through what the evidence actually shows, where it is strong, where it is thin, and the one safety rule almost every clinician agrees on.

The short version, and why the answer splits by group

There is no single answer to "do GLP-1 drugs affect fertility." The honest summary is that the effect depends almost entirely on who you are.

For women with obesity or polycystic ovary syndrome (PCOS), the signal is mostly favorable: weight loss tends to restart ovulation and regularize cycles, which can raise the odds of pregnancy. For men with obesity and low testosterone, several small studies show testosterone climbing and some sperm measures improving. But for people at a healthy weight, or anyone wanting to conceive in the near term, the picture is murkier and the most important fact is a safety one: these drugs are not considered safe in pregnancy, and you are supposed to stop them well before trying to conceive.

The biggest evidence gap is glaring. Almost all the human fertility data comes from people with PCOS or obesity. There is essentially no human trial data on fertility in women without PCOS, and the male data are small, short, and mostly in men who already had low testosterone. Anyone telling you GLP-1 drugs are a proven fertility treatment is running ahead of the science.

How GLP-1 drugs could touch fertility: the mechanism

GLP-1 (glucagon-like peptide-1) is a gut hormone. The drugs in this class copy it. They slow how fast the stomach empties, blunt appetite, and improve how the body handles insulin. Most of their effect on the reproductive system runs through two doors.

The indirect door (weight and insulin). Excess fat tissue and high insulin throw off reproductive hormones in both sexes. In women, insulin resistance pushes the ovaries to make more androgens (male-type hormones), which is a core driver of PCOS and the irregular or absent ovulation that comes with it. In men, obesity raises an enzyme called aromatase that converts testosterone into estrogen, dragging testosterone down. Drop the weight and improve insulin sensitivity, and these systems often swing back toward normal. This is the best-understood and most likely path for any fertility benefit.

The possible direct door (receptors in reproductive tissue). Researchers have found GLP-1 receptors in the ovary, the testis, and parts of the brain that control reproductive hormones. A systematic review on GLP-1 receptor agonists in reproductive health describes signaling that may influence ovarian cells and steroid production directly, not just through weight loss. This is biologically interesting but far from settled. Whether these receptors matter for human fertility, and whether the effect is helpful or harmful, is still an open question.

The two doors do not always push the same way. Weight loss is broadly good for fertility. A possible direct hormonal effect could help, do nothing, or, in theory, cause harm. That tension is why careful researchers hedge.

Women: the evidence by situation

Women with PCOS or obesity

This is where the data are strongest, and the news is mostly good.

PCOS is the most common cause of ovulation problems in women, and most women with PCOS carry extra weight and insulin resistance. GLP-1 drugs target exactly those problems. Studies in this group consistently show weight loss, lower fasting insulin, lower free testosterone, and higher sex hormone-binding globulin (which mops up excess androgens). The downstream effect is more regular periods and, often, a return of ovulation.

One frequently cited study treated obese PCOS patients who had failed lifestyle programs with semaglutide; a 2023 study of semaglutide in obese PCOS patients reported meaningful weight loss, better insulin sensitivity, and improved menstrual regularity. Other work has paired GLP-1 drugs with metformin and seen better cycle regularity and ovulation rates than either drug alone.

Here is the honest caveat. Most of this benefit travels through weight loss. Studies that separate the drug's "extra" effect from the effect of simply losing weight are rare and small. So the cleanest way to read the PCOS data is: GLP-1 drugs help women with PCOS lose weight, and weight loss restores fertility. That is a real benefit, but it is not the same as the drug having a unique fertility magic beyond what any effective weight-loss tool would do.

Women without PCOS or obesity

Here the evidence basically runs out. A 2025 analysis comparing social media perception to evidence-based medicine found a huge gap between online enthusiasm and actual science. Searches for "Ozempic babies" and "Ozempic fertility" exploded, with sentiment overwhelmingly positive. Yet the authors found dozens of peer-reviewed studies in women with PCOS and zero human studies measuring ovulation, implantation, IVF, or any fertility outcome in women without PCOS. The few animal studies they cite raised concerns, not reassurance.

So if you are a normal-weight woman without PCOS hoping a GLP-1 drug will boost your fertility, there is no human evidence to support that. The optimism online is not backed by trials.

The "Ozempic babies" effect: an accident, not a cure

Many of the surprise pregnancies behind the "Ozempic babies" headlines are not the drug improving fertility in a direct sense. Two more ordinary things are likely at play. First, weight loss alone restores ovulation in women who were not ovulating, so a person who assumed she could not get pregnant suddenly can. Second, and this matters most for tirzepatide users, the drug can make oral birth control less reliable. More on that in the safety section, because it is the single most important practical point in this whole article.

Table: GLP-1 effects on female fertility by group

Group	Likely effect on fertility	Strength of evidence	Main driver
Women with PCOS + obesity	Often improves: more regular cycles, restored ovulation	Moderate (multiple human studies, mostly small)	Weight loss + lower insulin and androgens
Women with obesity, no PCOS	Plausibly improves via weight loss	Weak (little direct fertility data)	Weight loss
Normal-weight women, no PCOS	Unknown; no human evidence	Very weak / none	N/A
Any woman trying to conceive now	Drug should be stopped first	Strong consensus on stopping	Safety, not fertility

Men: the evidence by situation

Men with obesity and low testosterone

The male data are smaller than the female data, but the pattern in men with obesity-linked low testosterone (often called functional hypogonadism) is fairly consistent and encouraging.

A controlled study of liraglutide in this group, Jensterle et al. on liraglutide and functional hypogonadism in men, found that 16 weeks of liraglutide produced solid weight loss and significantly raised total testosterone along with the pituitary hormones LH and FSH that drive the testes. A follow-up, a 2023 report on sexual and reproductive outcomes in obese men treated with liraglutide, described improvements in sperm count, motility, and the share of normally shaped sperm, plus better erectile function. Across the small human literature, most studies looking at sperm in obese men reported gains rather than harm.

Same caveat as the women: this is almost certainly weight loss doing the heavy lifting. Obesity suppresses testosterone, and losing weight lifts it back up. GLP-1 drugs are simply an effective way to lose weight.

Men at a healthy weight, or without low testosterone

This is where caution creeps in. A 2024 review titled a "fable of caution" on GLP-1 receptor agonists and male fertility lays out the worry plainly. In men who are not obese and do not have low testosterone, the upside is missing because there is no metabolic problem to fix, and a few signals hint at possible downside. The authors note that sperm production is a roughly three-month process, so even small disruptions could matter, and that GLP-1 signaling might, in some settings, lower testosterone production rather than raise it. There is also a single case report of a man whose sperm quality worsened on liraglutide and only partly recovered after stopping.

Read carefully, the male story is: helpful in men whose hormones were already knocked down by obesity, uncertain to possibly unhelpful in everyone else, and short on long-term data either way.

Table: GLP-1 effects on male fertility by group

Group	Reported effect	Strength of evidence	Notes
Men with obesity + low testosterone	Testosterone up; some sperm measures improve	Weak-to-moderate (small human studies)	Mostly driven by weight loss
Men with obesity, normal testosterone	Probable benefit via weight loss	Weak	Less specific data
Lean men, normal testosterone	Uncertain; possible neutral-to-mild negative	Very weak	"Fable of caution" review urges restraint
Any man planning conception soon	No clear reason to start for fertility	N/A	Discuss timing with a clinician

The non-negotiable safety issue: pregnancy and birth control

If you remember one thing from this article, make it this. GLP-1 drugs are not considered safe to use during pregnancy, and the standard advice is to stop them before trying to conceive.

Why pregnancy is off-limits

Animal studies raised clear red flags. The FDA prescribing information for Wegovy (semaglutide) reports that in pregnant rats, semaglutide caused embryo-fetal death, structural abnormalities, and growth changes at exposures below the maximum human dose, with early pregnancy losses and abnormalities also seen in rabbits and monkeys. Human pregnancy data are limited, so the label states the drug should not be used in pregnancy and should be discontinued in advance of a planned pregnancy.

The washout period

Semaglutide hangs around in the body for a while; its half-life is about a week. Because of that long tail, the standard guidance is to stop semaglutide at least two months before trying to conceive so the drug is fully cleared before a pregnancy begins. Tirzepatide has a somewhat shorter half-life, but the same roughly two-month-ahead approach is commonly recommended. If you become pregnant unexpectedly while taking one of these drugs, stop it and call your doctor; that is the consistent advice across labels and clinicians.

The birth control trap that explains many "Ozempic babies"

This is the practical landmine. Tirzepatide slows stomach emptying enough to change how the body absorbs oral medications, including the pill. The FDA prescribing information for Mounjaro (tirzepatide) warns that tirzepatide may reduce the effectiveness of oral hormonal contraceptives and advises switching to a non-oral method (like an IUD or implant) or adding a barrier method such as condoms for four weeks after starting the drug and for four weeks after each dose increase. Pharmacokinetic testing found the pill's key estrogen component dropped meaningfully in blood levels after a tirzepatide dose.

Pair that with weight loss restoring ovulation in someone who thought she could not conceive, and you get exactly the surprise-pregnancy pattern behind the headlines. Semaglutide does not carry the same explicit pill warning, but any drug that slows the gut can in theory affect absorption, so the safest move on any GLP-1 drug is to use reliable, non-oral contraception if you do not want to be pregnant.

Table: pregnancy and contraception rules at a glance

Question	Practical answer
Safe to use during pregnancy?	No. Labels advise against it; animal data show harm
When to stop before trying to conceive?	About 2 months ahead (semaglutide and tirzepatide)
Does it weaken the pill?	Tirzepatide: yes, label warns and advises backup. Semaglutide: not formally labeled, but caution is wise
Recommended birth control on the drug?	Non-oral (IUD, implant, injection) or add a barrier method
Got pregnant by surprise?	Stop the drug and call your clinician right away

How this compares to other fertility approaches

GLP-1 drugs are not a fertility treatment, and it helps to see where they sit next to options that are.

For women with PCOS who want to conceive, first-line medical care still centers on ovulation-induction drugs like letrozole, sometimes with metformin, plus lifestyle change. A GLP-1 drug might be used beforehand to lose weight and improve ovulation, then stopped for the washout window before actively trying. It is a preconception tune-up, not a conception tool. The catch is timing: you cannot be on the drug while trying to get pregnant, so any fertility benefit has to bank during the weight-loss phase and carry over after you stop.

For men with obesity-linked low testosterone, the comparison is often testosterone replacement therapy (TRT). TRT raises testosterone but typically shuts down the body's own sperm production, which is a problem for a man who wants children. A GLP-1 drug, by contrast, raises testosterone through the body's natural pathway and does not appear to suppress sperm in the way TRT does, which is one reason researchers find it appealing for men who want both higher testosterone and preserved fertility. Still, the data are early.

Plain weight loss by any means, including dedicated GLP-1 diet and nutrition strategies, delivers many of the same fertility benefits, which underscores that weight loss is the active ingredient here.

Who this is and is not for

A reasonable conversation to have with a clinician:

A woman with PCOS and obesity who wants to lose weight and improve cycles before trying to conceive later, with a clear plan to stop the drug in time.
A man with obesity and documented low testosterone, especially one who wants to preserve fertility and is weighing this against TRT.
Anyone using a GLP-1 drug mainly for weight or metabolic health who needs to understand the contraception rules.

Where the case is weak or the answer is no:

A normal-weight woman without PCOS hoping for a fertility boost. No human evidence supports this.
A lean man with normal testosterone looking to improve sperm. The data lean neutral-to-cautious, not beneficial.
Anyone actively trying to conceive right now. The drug should be stopped first.
Anyone pregnant or who could become pregnant without reliable contraception.

Side effects matter to the decision too. Nausea, vomiting, and diarrhea are common, especially early, and on top of being unpleasant they can in theory worsen absorption of an oral pill. For the full rundown, see the complete guide to GLP-1 side effects. And because rapid weight loss can cost muscle, anyone on these drugs should pay attention to preventing muscle loss on GLP-1 medications and protein intake.

Reading the evidence honestly

A few things are worth saying flat out. The fertility benefits in PCOS and in obese hypogonadal men are real but mostly a downstream effect of weight loss, not proof of a special fertility action. The human studies are small, often short, and concentrated in people who had a metabolic problem to begin with. There is almost no human fertility data outside PCOS and obesity. The online buzz about "Ozempic babies" has outrun the science, and much of that phenomenon is explained by restored ovulation plus weakened birth control, not by the drugs being a fertility treatment. And the firmest, least controversial point in the whole field is the safety rule: do not use these drugs in pregnancy, and stop them before trying to conceive.

For anyone weighing the bigger picture of who benefits from these medications and who does not, the GLP-1 by subgroup evidence review for PCOS, prediabetes, NAFLD, and cardiovascular disease puts the fertility question in context with the rest of the metabolic story.

Frequently Asked Questions

Can GLP-1 drugs help me get pregnant?

Indirectly, and only in specific situations. For women with PCOS or obesity, the weight loss and lower insulin these drugs cause can restart ovulation and make pregnancy more likely. But the drug itself is not a fertility treatment, the benefit comes mainly from weight loss, and you must stop the drug before actively trying to conceive because it is not safe in pregnancy.

Do I have to stop my GLP-1 drug before trying to conceive?

Yes. The standard advice is to stop semaglutide or tirzepatide about two months before trying to get pregnant, because the drug lingers in the body and animal studies showed harm to developing offspring. If you become pregnant unexpectedly while taking one, stop it and contact your doctor right away.

Can a GLP-1 drug make my birth control fail?

It can, especially tirzepatide. The Mounjaro label warns that tirzepatide may reduce the effectiveness of oral birth control pills and recommends a non-oral method or an added barrier method for four weeks after starting and after each dose increase. This, combined with restored ovulation from weight loss, helps explain the surprise pregnancies people call "Ozempic babies."

Do GLP-1 drugs lower or raise testosterone in men?

In men with obesity and low testosterone, small studies show testosterone rising, along with improvements in some sperm measures, mostly because of weight loss. In lean men with normal testosterone, the picture is uncertain and some researchers warn of a possible neutral-to-mild negative effect, so there is no good reason to start one purely to boost fertility if your weight and testosterone are already normal.

Is there strong proof that GLP-1 drugs improve fertility?

No. The evidence is moderate at best in PCOS and obese hypogonadal men, and it is largely explained by weight loss rather than a unique drug effect. There is essentially no human fertility data in normal-weight people without PCOS. Anyone presenting these drugs as a proven fertility treatment is overstating what the science shows.

This article is for general education only and is not medical advice. Talk to a qualified healthcare provider about your own situation, especially before starting, stopping, or changing any medication, or if you are pregnant or trying to conceive.